The sulfamide motif in the design of enzyme inhibitors

被引:78
|
作者
Winum, JY
Scozzafava, A
Montero, JL
Supuran, CT
机构
[1] Univ Montpellier 2, Lab Chim Biomol, UMR 5032, Ecole Natl Super Chim Montpellier, F-34296 Montpellier, France
[2] Univ Florence, Dipartimento Chim, Chim Bioorgan Lab, I-50019 Sesto Fiorentino, Firenze, Italy
关键词
gamma-secretase; carbonic anhydrase inhibitor; carboxypepridase A; chymase; elastase; enzyme-inhibitor adduct; HIV protease; matrix metalloproteinase; protease inhibitor; protein tyrosine phosphatase; steroid sulfatase inhibitor; sulfamide; thrombin; tryptase;
D O I
10.1517/13543776.16.1.27
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The sulfamide moiety, similarly to the structurally related sulfonamide and sulfamate ones, is widely employed in medicinal chemistry for the design of biologically active compounds. Amongst the enzymes for which sulfamide-based inhibitors were designed are the carbonic anhydrases (CAs), and a large number of proteases belonging to the aspartic protease (HIV-1 protease, gamma-secretase), serine protease (elastase, chymase, tryptase and thrombin, among others) and metalloproteinase (carboxypeptidase A [CPA] and matrix metalloproteinase [MMP]) families. Some steroid sulfatase (STS) and protein tyrosine phosphatase inhibitors belonging to the sulfamide class of derivatives have also been reported. In all these compounds, many of which show low nanomolar affinity for the target enzymes for which they have been designed, the free or substituted sulfamide moiety plays an important role in the binding of the inhibitor to the active site cavity. This is achieved either by directly coordinating to the metal ion found in some metalloenzymes (CAs, CPA, STS), usually by means of one of the nitrogen atoms present in the sulfamide motif, or, as in the case of the cyclic sulfamides, acting as HIV protease inhibitors interacting with the catalytically critical aspartic acid residues of the active site by means of an oxygen atom belonging to the HN-SO2-NH motif that substitutes a catalytically essential water molecule. In other cases, the sulfamide moiety is important for inducing desired physicochemical properties to the drug-like compounds incorporating it, such as enhanced water solubility, better bioavailability etc., due to the intrinsic properties of this highly polarised moiety when attached to an organic scaffold. This interesting motif is, thus, of great value for the design of pharmacological agents with many applications.
引用
收藏
页码:27 / 47
页数:21
相关论文
共 50 条
  • [1] Sulfamide as Zinc Binding Motif in Small Molecule Inhibitors of Activated Thrombin Activatable Fibrinolysis Inhibitor (TAFIa)
    Halland, Nis
    Czech, Joerg
    Czechtizky, Werngard
    Evers, Andreas
    Follmann, Markus
    Kohlmann, Markus
    Schreuder, Herman A.
    Kallus, Christopher
    JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (20) : 9567 - 9573
  • [2] Cyclic sulfamide γ-secretase inhibitors
    Sparey, T
    Beher, D
    Best, J
    Biba, M
    Castro, JL
    Clarke, E
    Hannam, J
    Harrison, T
    Lewis, H
    Madin, A
    Shearman, M
    Sohal, B
    Tsou, N
    Welch, C
    Wrigley, J
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (19) : 4212 - 4216
  • [3] Design, Synthesis, and Characterization of Sulfamide and Sulfamate Nucleotidomimetic Inhibitors of hHint1
    Shah, Rachit
    Strom, Alexander
    Zhou, Andrew
    Maize, Kimberly M.
    Finzel, Barry C.
    Wagner, Carston R.
    ACS MEDICINAL CHEMISTRY LETTERS, 2016, 7 (08): : 780 - 784
  • [4] A new structural motif for the design of potent glucosidase inhibitors
    Tanaka, KSE
    Winters, GC
    Batchelor, RJ
    Einstein, FWB
    Bennet, AJ
    JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2001, 123 (05) : 998 - 999
  • [5] Design of angiotensin converting enzyme inhibitors
    David W. Cushman
    Miguel A. Ondetti
    Nature Medicine, 1999, 5 : 1110 - 1112
  • [6] DFT design of inhibitors of the LPXC enzyme
    Dishuck, Carolyn
    Dewar, Allison
    Peterson, Larryn
    Cafiero, Mauricio
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 251
  • [7] Design and mechanism of enzyme inhibitors.
    Silverman, RB
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 226 : U159 - U159
  • [8] Design of angiotensin converting enzyme inhibitors
    Cushman, DW
    Ondetti, MA
    NATURE MEDICINE, 1999, 5 (10) : 1110 - 1112
  • [9] DFT design of inhibitors of the LpxC enzyme
    Dishuck, Carolyn
    Roldan, Rebeca
    Dewar, Allison
    Peterson, Larryn
    Cafiero, Mauricio
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 253
  • [10] Design of β-Amyloid Aggregation Inhibitors from a Predicted Structural Motif
    Novick, Paul A.
    Lopes, Dahabada H.
    Branson, Kim M.
    Esteras-Chopo, Alexandra
    Graef, Isabella A.
    Bitan, Gal
    Pande, Vijay S.
    JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (07) : 3002 - 3010